Driven by DRG’s oncology expertise and real-world data capabilities, the Real World Brand Tracker is an interactive dashboard of regularly updated U.S. claims data that monitors and highlights the shifting market dynamics and the impact of events on immune checkpoint inhibitor prescribing.

QUESTIONS ANSWERED

How is the uptake for individual brands changing over time and across different U.S. regions and individual states?

Which brand is winning, and how does that vary by indication?

How does the dynamic regulatory environment for immune checkpoint inhibitor brands in the United States affect prescribing patterns of currently approved brands by indication?

What is the average claim charge for each brand? How does this compare to the reimbursed amount? How does each of these metrics vary by payer type?

In which types of facilities are patients receiving these brands?

KEY BENEFITS AND USES

Understand evolving market dynamics and correlate clinical and regulatory events to brand use by indication.

Track number of patients treated with immune checkpoint inhibitor brands over time.

Segment the data in multiple ways, including by state and treatment setting, to reveal pockets of opportunity.

Visualize trends in payer metrics including total claim amount, total claim paid, and top payers for immune checkpoint inhibitors.

Design appropriate clinical trial strategies based on rapidly evolving standards in treatment practices, as revealed by claims data.

Uncover pockets of opportunity for improved penetration and identify segments where brands are performing poorly.

Table of contents

  • Real World Brand Tracker
    • Dashboard Access
      • Dashboard Access

Author(s): Neela Rambaruth

Neela Rambaruth is a Business Insights Analyst in the Oncology division at DRG. Neela joined DRG in 2018 and has since authored the Disease Landscape and Forecast report for non-small-cell lung cancer. Neela is currently working on the Disease Landscape and Forecast report for Hepatocellular carcinoma and the survey for Immune checkpoint US Access and Reimbursement. Prior to joining DRG, Neela Rambaruth was a Postdoctoral Scientist at University College London, where she investigated the interaction of novel drugs with a therapeutic receptor involved in cardiovascular ; She also held another postdoctoral position at Imperial College London, where she studied host-pathogen interaction in tuberculosis. Dr Rambaruth holds a PhD in Breast Oncology from the University of ; Her doctorate focused on the identification of novel biomarkers associated with metastatic breast cancer. She has also published several peer-reviewed articles in oncology and therapeutic drug discovery.